In T-ALL patients, we observe that the percentage of promoter methylation in the CDKN2B and CDKN2A genes ranges between 46% and 68%, and between 0% and 12%, respectively, in pediatric cohorts (Table 3). This evidence concerns the gene CDKN2A and acute lymphoblastic leukemia.